Epoprostenol vs Ralinepag

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Pulmonary Arterial Hypertension

Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Arterial Hypertension pipeline

Epoprostenol · Flolan

Rights held by GlaxoSmithKline; US product discontinued

Approved in Pulmonary Arterial Hypertensionsmall molecule (prostacyclin)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Ralinepag

Developed by United Therapeutics under a licence from Arena Pharmaceuticals, Inc.

Phase 3 in Pulmonary Arterial Hypertensionsmall molecule
Reliable signal

NCT03626688 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled, event-driven Phase 3 trial with 687 patients in the full analysis set (728 randomized; 41 patients from sites in China excluded), measuring time to first clinical worsening event as the primary endpoint. The peer-reviewed report in The Lancet gives a hazard ratio of 0.45 (95% CI 0.33-0.62; p<0.0001) for ralinepag versus placebo, with more discontinuations for adverse events on ralinepag (19% vs 3%).

Next expected readout: December 2026 · NCT03683186 (registry estimate)

Reported efficacy

Time from randomization to the first adjudicated protocol-defined clinical worsening event (The study duration was event-based. This parameter was assessed from randomization until the conclusion of the study, up to 3 years): Time to first adjudicated clinical worsening event (ADVANCE OUTCOMES): HR 0.45 (95% CI 0.33-0.62) vs placebo, a 55% risk reduction, p<0.0001. (met)

Result source: NCT03626688

Results for Pulmonary Arterial Hypertension

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Epoprostenol: 5 of 6 rows · Ralinepag: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEpoprostenol
Rows use multiple source trials
Ralinepag
Rows use multiple source trials
6MWD - Change
absolute change · m
288 vs 323.5 Epoprostenol Sodium for Injection m @ 4wka,b,c,d
NCT01105091 · Phase 4 · registry result, not featured evidence
36.2 vs 29.4 placebo m @ 22wka,b,c,d
NCT02279160 · Phase 2 · registry result, not featured evidence
6MWD - Change
absolute change · m
No placebo or comparator arm
-3.55 m @ 4wka,e,c,f
NCT01462565 · Phase 4 · registry result, not featured evidence
-120 m @ 221wka,e,c,f
NCT02279745 · Phase 2 · registry result, not featured evidence
Dropout rate
0%g
NCT01462565 · Phase 4 · registry result, not featured evidence
show 2 more results
0%
NCT01105117 · Phase 4 · registry result, not featured evidence
10%
NCT01105091 · Phase 4 · registry result, not featured evidence
44.4%g
NCT02279745 · Phase 2 · registry result, not featured evidence
show 1 more result
15%
NCT02279160 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—g
NCT01462565 · Phase 4 · registry result, not featured evidence
show 2 more results
—
NCT01105117 · Phase 4 · registry result, not featured evidence
—
NCT01105091 · Phase 4 · registry result, not featured evidence
15.6%g
NCT02279745 · Phase 2 · registry result, not featured evidence
show 1 more result
—
NCT02279160 · Phase 2 · registry result, not featured evidence
Serious AEs
12.5%g
NCT01462565 · Phase 4 · registry result, not featured evidence
show 2 more results
0%
NCT01105117 · Phase 4 · registry result, not featured evidence
30%
NCT01105091 · Phase 4 · registry result, not featured evidence
46.7%g
NCT02279745 · Phase 2 · registry result, not featured evidence
show 1 more result
10%
NCT02279160 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
g
diarrhoea 12.5%
fatigue 12.5%
headache 12.5%
NCT01462565 · Phase 4 · registry result, not featured evidence
show 2 more results
catheter site erythema 100%
flushing 0%
NCT01105117 · Phase 4 · registry result, not featured evidence
pain in jaw 75%
headache 65%
nausea 50%
NCT01105091 · Phase 4 · registry result, not featured evidence
g
headache 64.4%
diarrhoea 37.8%
pain in jaw 33.3%
NCT02279745 · Phase 2 · registry result, not featured evidence
show 1 more result
headache 77.5% (placebo 28.6%)
nausea 50% (placebo 23.8%)
diarrhoea 47.5% (placebo 14.3%)
NCT02279160 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 4 versus Phase 2.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 4 weeks versus 22 weeks.
  5. ePopulation context differs: registered conditions differ.
  6. fAssessment timepoints differ: 4 weeks versus 221 weeks.
  7. gPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Epoprostenol

SF-36 Physical Functioning -1.156 score @ 4wk
absolute change · score
No placebo or comparator arm
Physical Functioning
NCT01462565 · Phase 4 · registry result, not featured evidence
SF-36 - Role Physical -0.765 score @ 4wk
absolute change · score
No placebo or comparator arm
Role-Physical
NCT01462565 · Phase 4 · registry result, not featured evidence
SF-36 - Role Emotional 0.002 score @ 4wk
absolute change · score
No placebo or comparator arm
Role-Emotional
NCT01462565 · Phase 4 · registry result, not featured evidence
SF-36 Vitality 0.781 score @ 4wk
absolute change · score
No placebo or comparator arm
Vitality
NCT01462565 · Phase 4 · registry result, not featured evidence
SF-36 Social Functioning 1.706 score @ 4wk
absolute change · score
No placebo or comparator arm
Social Functioning
NCT01462565 · Phase 4 · registry result, not featured evidence
SF-36 Bodily Pain 3.065 score @ 4wk
absolute change · score
No placebo or comparator arm
Bodily Pain
NCT01462565 · Phase 4 · registry result, not featured evidence
SF-36 General Health -0.606 score @ 4wk
absolute change · score
No placebo or comparator arm
General Health
NCT01462565 · Phase 4 · registry result, not featured evidence
SF-36 Physical Component Summary -0.123 score @ 4wk
absolute change · score
No placebo or comparator arm
Physical Health Component
NCT01462565 · Phase 4 · registry result, not featured evidence
Borg Dyspnea 0.36 score @ 4wk
absolute change · score
No placebo or comparator arm
NCT01462565 · Phase 4 · registry result, not featured evidence
SvO2 58% (n=11) vs 56% (n=6) Epoprostenol Sodium for Injection @ 4wk
absolute change · percentage points
NCT01105091 · Phase 4 · registry result, not featured evidence

Ralinepag

PVR Change Dyn S Cm5 -52.2 seconds
absolute change · seconds
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence
Time to First Clinical Worsening Event 13.04 months
time to event · months
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence · converted to months from 56.5 weeks as posted
6MWD - Change 37 m
absolute change · m
No placebo or comparator arm
End of Study (Time of Discontinuation of Study by Sponsor)
NCT02279745 · Phase 2 · registry result, not featured evidence
Cardiac Output 0 L/min
absolute change · L/min
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence
Cardiac Index Change L/Min M2 0 L/min
absolute change · L/min
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence
Pulmonary Arterial Pressure -2 mmHg
absolute change · mmHg
No placebo or comparator arm
NCT02279745 · Phase 2 · registry result, not featured evidence
PVR 514.6 vs 512 placebo cm @ 22wk
absolute change · cm
NCT02279160 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Epoprostenol's landscape · Ralinepag's landscape